| Item Type | Name |
|
Concept
|
Survival Analysis
|
|
Academic Article
|
Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer.
|
|
Academic Article
|
Serum interleukin-6 levels in metastatic renal cell cancer: correlation with survival but not an independent prognostic indicator.
|
|
Academic Article
|
Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer.
|
|
Academic Article
|
Gemcitabine doublets in advanced urothelial cancer.
|
|
Academic Article
|
Docetaxel and exisulind in hormone-refractory prostate cancer.
|
|
Academic Article
|
Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck.
|
|
Academic Article
|
A phase II trial of oral temozolomide in patients with metastatic renal cell cancer.
|
|
Academic Article
|
Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma.
|
|
Academic Article
|
9-Nitrocamptothecin as second line chemotherapy for men with progressive, metastatic, hormone refractory prostate cancer: Results of the CALGB 99901.
|
|
Academic Article
|
Long-term survival in phase II trials of gemcitabine plus cisplatin for advanced transitional cell cancer.
|
|
Academic Article
|
Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663.
|
|
Academic Article
|
A Phase II study of oxaliplatin in urothelial cancer.
|
|
Academic Article
|
Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma.
|
|
Academic Article
|
A Phase I/II study of GTI-2040 and capecitabine in patients with renal cell carcinoma.
|
|
Academic Article
|
Phase 2 trial of talactoferrin in previously treated patients with metastatic renal cell carcinoma.
|
|
Academic Article
|
A Phase II trial of suramin monthly x 3 for hormone-refractory prostate carcinoma.
|
|
Academic Article
|
A multi-institutional phase II trial of gemcitabine plus paclitaxel in patients with locally advanced or metastatic urothelial cancer.
|
|
Academic Article
|
Transcriptional profiles in peripheral blood mononuclear cells prognostic of clinical outcomes in patients with advanced renal cell carcinoma.
|
|
Academic Article
|
Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma.
|
|
Academic Article
|
Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862): trial results and interleukin-6 analysis: a study by the Department of Defense Prostate Cancer Clinical Trial Consortium and University of Chicago Phase 2 Consortium.
|
|
Academic Article
|
A phase II study of gemcitabine and capecitabine in metastatic renal cancer: a report of Cancer and Leukemia Group B protocol 90008.
|
|
Academic Article
|
Safety and efficacy of sorafenib in elderly patients treated in the North American advanced renal cell carcinoma sorafenib expanded access program.
|
|
Academic Article
|
Effective therapy for metastatic renal cancer, whither to now.
|
|
Academic Article
|
A phase II trial of sequential chemotherapy with docetaxel and methotrexate followed by gemcitabine and cisplatin for metastatic urothelial cancer.
|
|
Academic Article
|
A phase II study of the efficacy and safety of AMG 102 in patients with metastatic renal cell carcinoma.
|
|
Academic Article
|
A phase II study of PS-341 (Bortezomib) in advanced or metastatic urothelial cancer. A trial of the Princess Margaret Hospital and University of Chicago phase II consortia.
|
|
Academic Article
|
Randomization reveals unexpected acute leukemias in Southwest Oncology Group prostate cancer trial.
|
|
Academic Article
|
Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583).
|
|
Academic Article
|
Adoptive immunotherapy by allogeneic stem cell transplantation for metastatic renal cell carcinoma: a CALGB intergroup phase II study.
|
|
Academic Article
|
A phase II trial of gemcitabine, capecitabine, and bevacizumab in metastatic renal carcinoma.
|
|
Academic Article
|
Baseline patient-reported kidney cancer-specific symptoms as an indicator for median survival in sorafenib-refractory metastatic renal cell carcinoma.
|
|
Academic Article
|
Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trials.
|
|
Academic Article
|
Progression-free survival as a surrogate endpoint of overall survival in patients with metastatic renal cell carcinoma.
|
|
Academic Article
|
Long-term survival and biomarker correlates of tasquinimod efficacy in a multicenter randomized study of men with minimally symptomatic metastatic castration-resistant prostate cancer.
|
|
Academic Article
|
Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial.
|
|
Academic Article
|
Clinical Evaluation of Cisplatin Sensitivity of Germline Polymorphisms in Neoadjuvant Chemotherapy for Urothelial Cancer.
|
|
Academic Article
|
Prognostic importance of lymphovascular invasion in urothelial carcinoma of the renal pelvis.
|
|
Academic Article
|
A randomized phase 2 network trial of tivantinib plus cetuximab versus cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma.
|
|
Academic Article
|
Randomized Phase III Trial of Gemcitabine and Cisplatin With Bevacizumab or Placebo in Patients With Advanced Urothelial Carcinoma: Results of CALGB 90601 (Alliance).
|